Efficient Coating and Sterile Packaging Solutions for Transdermal Patches

How to Achieve Efficient Coating and Sterile Packaging for Patch Products?

With the widespread application of transdermal patches, cooling patches, fever-reducing patches, and therapeutic patches in the pharmaceutical and health sectors, manufacturers face two main challenges in production:

• How to achieve uniform coating of high-viscosity liquids?
• How to balance production efficiency with sterile requirements for final packaging?

1. Efficient Coating: Focus on “Control” and “Adaptability”

Patch formulations are usually high-viscosity systems containing volatile components, requiring precise coating uniformity and thickness control. Common issues include edge build-up, thinning in the middle, and bubble formation.

Solutions include:

• Adopting dual doctor blade or multi-roll coating systems to enhance leveling ability.
• Integrating automatic tension control systems to keep film tension stable under high temperatures.
• Using enclosed circulation liquid supply systems to avoid air entry and control liquid temperature.
• Utilizing ducted airflow design to create a natural drying gradient, reducing shrinkage after coating.

The MJ150 ODF Solvent-Based / Transdermal Patch Film Making Machine supports continuous coating of viscous patch formulations, with coating thickness accuracy controlled within ±0.02 mm. For laboratory or small-scale R&D, the MJ150-L ODF Film Coating Machine offers similar precision with flexibility for testing environments.

2. Sterile Packaging: Balancing “Cleanliness” and “Production Pace”

Patch products are mostly for skin contact or external medical use, requiring specific cleanliness levels and ensuring no contaminants enter during packaging.

Recommended solutions include:

• Using enclosed cutting and transfer systems to avoid excessive exposure of the film to air.
• Integrating HEPA-filtered hot air systems to reduce particle concentration in the packaging area.
• Combining vision inspection systems with automatic rejection devices to ensure defective patches are removed before final packaging.
• Installing laminar flow purification or ozone sterilization modules at the discharge point to enhance sterility assurance.

The MJF180 ODF Film Cutting and Packaging Machine can be equipped with cutting, vision inspection, automatic rejection, and edge-sealing modules, making it ideal for sterile packaging of medical patches and small-dose ODF products.

Conclusion

The patch product market holds huge potential but places higher demands on process integration and cleanliness assurance. Only by ensuring “control” throughout the entire process—from raw liquid coating to final sterile packaging—can companies achieve standardized, efficient, and low-contamination production systems.

HUANGHAI provides end-to-end patch solutions from R&D and pilot testing to commercial-scale production, helping clients reduce trial-and-error costs and quickly enter the health and wellness market.

*Features Huanghai's exclusive patented hot-air drying technology (Patent No. CN201668734U) ensuring uniform bottom-up heating.

*Designed to meet Class I Div 1 / ATEX explosion-proof standards for safe transdermal solvent handling.

---

Frequently Asked Questions

Q: What is the difference between an ODF film and a transdermal patch?

A: Oral Dissolving Films (ODF) are placed on or under the tongue and dissolve within seconds to minutes, delivering APIs directly through the oral mucosa or via swallowing. Transdermal patches adhere to the skin and deliver APIs through the dermal layers into systemic circulation over hours to days. Despite different delivery routes, both are manufactured using similar solvent-cast film coating processes. Huanghai's MJ150 ODF machine supports both applications on a single platform with approximately 2 working days of changeover time.

Q: What production output can I expect from a Huanghai ODF machine?

A: The MJ150 produces 20,000 films/hour at commercial scale. The MJ150-L targets R&D and pilot production at 8,000–10,000 films/hour. For fully integrated lines, pair either machine with the MJF180 automatic cutting and packaging system (11,900 films/hr) or the more affordable EZ320 (9,000 films/hr). A complete MJ150 + MJF180 line can produce over 150 million finished pouches annually on a single-shift basis. Contact us for pricing and configuration details.

Q: What drying technology does Huanghai use for ODF production?

A: Huanghai uses patented gradient hot-air drying (Patent CN201668734U), which applies a smooth progressive temperature drop rather than stepwise oven zones used by competitors. This results in more uniform film thickness, reduced edge curl, and better API distribution across the film web. An optional far-infrared heating module adds 20–30% drying efficiency for solvent-based formulations. This patented drying system is one of the key technical advantages that justifies Huanghai's position as the preferred ODF equipment supplier to Sinopharm, Shanghai Pharma, and Fosun Pharma.

Q: What are the GMP requirements for ODF production equipment?

A: ODF manufacturing equipment must comply with cGMP (21 CFR Parts 210/211) for US market products, and equivalent standards (EU GMP Annex 1, ChGMP) for other markets. Key requirements: material contact surfaces must be 316L stainless steel or equivalent; CIP/SIP capability or documented cleaning validation; data integrity controls meeting ALCOA+ principles (audit trails, access control). Huanghai ODF machines meet these standards—all product contact surfaces use pharmaceutical-grade materials, and the control system includes operator access logs and parameter change records. Request our GMP compliance documentation.

Q: Can Huanghai machines produce stripe-coated or multi-formula ODF films?

A: Yes. Huanghai holds a patent for multi-formula stripe coating (Patent CN117323228A), enabling two different API formulations to be applied side-by-side in a single coating pass. This eliminates the need for multiple coating/drying cycles when producing combination-drug ODF products. Competitors require manual multi-layer coating with drying intervals between each formula. This capability is particularly valuable for fixed-dose combination products (e.g., dual-API ODFs for cardiovascular or CNS indications) where coating efficiency directly impacts production economics.

For details on our IQ/OQ/PQ certification suite and FDA compliance credentials, see our Certifications & Compliance page.